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Abstract
Clinical reports have demonstrated that higher rates of non-diabetic glomerulosclerosis in African 
Americans can be attributed to two coding sequence variants (G1 and G2) in the APOL1 gene; 
however, the underlying mechanism is still unknown. Kidney biopsy data suggest enhanced 
expression of APOL1/APOL1 variants (Vs) in smooth muscle cells (SMCs) of renal vasculature. 
Since APOL1 is a secretory protein of relatively low molecular weight (41 kDa), SMCs may be a 
contributory endocrine/paracrine source of APOL1 wild type (WT)/APOL1Vs in the glomerular 
capillary perfusate percolating podocytes. In the present study, we tested the hypothesis that an 
HIV milieu stimulated secretion of APOL1 and its risk variants by arterial SMCs contributes to 
podocyte injury. Human umbilical artery smooth muscle cells (HSMCs)-treated with conditioned 
media (CM) of HIV-infected peripheral mononuclear cells (PBMC/HIV-CM), CM of HIV-
infected U939 cells, or recombinant IFN-γ displayed enhanced expression of APOL1. Podocytes 
co-cultured in trans-wells with HSMCs-over expressing APOL1WT showed induction of injury; 
however, podocytes co-cultured with HSMC-over expressing either APOL1G1 or APOL1G2 
showed several fold greater injury when compared to HSMC- over expressing APOL1WT. 
Conditioned media collected from HSMC-over-expressing APOL1G1/APOL1G2 (HSMC/
APOL1G1-CM or HSMC/APOL1G2-CM) also displayed higher percentages of injured podocytes 
in the form of swollen cells, leaky lysosomes, loss of viability, and enhanced sensitivity to adverse 
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host factors when compared to HSMC/APOL1WT-CM. Notably, HSMC/APOL1WT-CM 
promoted podocyte injury only at a significantly higher concentrations compared to HSMC/
APOL1G1/G2-CM. We conclude that HSMCs could serve as an endocrine/paracrine source of 
APOL1Vs, which mediate accelerated podocyte injury in HIV milieu.
Introduction
Compared with European Americans (EAs), African Americans (AAs) develop 4–5 fold 
higher rates of progressive nephropathy including focal segmental glomerulosclerosis 
(FSGS), and hypertension-attributed chronic kidney disease (CKD) [Tzur et al, 2010; Kopp 
et al, 2011; Quaggin and George, 2011], and this disparity reaches a greater than 10-fold 
difference in the case of HIV-associated nephropathy (HIVAN) [Genovese et al, 2010]. 
Recent clinical reports have shown that this major health disparity is strongly associated 
with two coding sequence variants (G1 and G2) in APOL1 [Friedman et al, 2011;; Genovese 
et al, 2010, 2013; Foster et al, 2013], but the underlying mechanisms are only beginning to 
be elucidated [Lan et al, 2014; Nichols et al, 2014; Thomson et al, 2014]. It is controversial 
whether APOL1 nephropathy risk alleles associate with atherosclerosis or protection from 
calcified atherosclerotic plaque and improved survival (Freedman et al 2015; Ito et al, 2014; 
Langefeld, 2015). Ito et al reported heightened risk for myocardial infarction with APOL1 
risk variants, despite simultaneous association with lower coronary artery calcified plaque 
(Ito et al, 2014); however, these findings are not supported by two follow-up analyses 
(Freedman et al, 2015; Langefeld et al, 2015).
Podocytes, the highly differentiated cells play a cardinal role in the maintenance of the 
glomerular filtration barrier. Podocytopathy (altered podocyte phenotype, reduction in 
number and effacement of foot processes) is usually associated with proteinuric diseases 
including HIVAN [Mundel and Shankland, 2002; Medapalli et al, 2011]. In previous 
studies, we demonstrated that APOL1 risk variants (Vs) G1 and G2 induce necrosis in 
podocytes and make them vulnerable to adverse host factors (AHFs) such as HIV infection 
[Lan et al, 2014]. Those studies revealed a causal relationship between podocyte injury and 
expression of APOL1Vs, thus providing a potential mechanistic basis for the observed 
disparity in chronic kidney disease (CKD) in relation to APOL1 genotype. An observation 
of interest in these studies was that inhibition of uptake of APOL1 reduced podocyte injury. 
These findings suggested a possible role for extracelluar APOL1 in podocyte injury, which 
is of potential relevance in view of the fact that APOL1 is the only member of the APOL1-6 
family cluster with a signal peptide [Page et al, 2001]; however, in vivo, secretion of APOL1 
may be from podocytes (autocrine), adjacent cells (paracrine), or from distant cells 
(endocrine).
Although APOL1Vs enhance podocyte injury in HIV milieu, it is not clear whether HIV 
contributes to accelerated podocyte injury through enhanced APOL1 expression in 
podocytes themselves or whether other sources also contribute. Of note, kidney biopsy 
specimens from HIVAN patients did not reveal upregulation of APOL1 in podocytes 
[Madhavan et al, 2011]. On the other hand, podocyte APOL1 expression has been reported 
to be attenuated both in FSGS and HIVAN [Madhavan et al, 2011]. Thus, it appears that 
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either the source of APOL1 contributing to kidney cell injury was not from these cells or 
those mechanisms wherein loss of APOL1 may be compromising the viability of podocytes 
is responsible for injury. The latter formulation seems less likely given the finding that 
absence of APOL1 does not alter the podocyte phenotype, and that APOL1 is dispensable 
for kidney health [Johnstone et al, 2002; Lan et al, 2014; Thomson et al, 2014]. Nonetheless, 
the source of APOL1 contributing to kidney cell injury in HIVAN remains elusive. This 
leads to the alternative formulation that the mere presence of HIV infection either renders 
APOL1Vs expressing podocytes vulnerable to injury and/or compromises their rescue 
strategy in the presence of adverse factors. This concept is also supported by recent reports 
in which circulating levels of APOL1 did not correlate with CKD parameters in a cohort of 
patients with HIVAN (Bruggeman et al, 2014).
Human podocytes have been reported to endocytose exogenous APOL1 [Ma et al, 2015]. 
We also demonstrated that uptake of secretory APOL1Vs was associated with podocyte 
injury [Lan et al, 2014]. Madhavan et al reported that APOL1 expression in small arterial 
and arteriolar smooth muscle cells (SMCs) is increased both in FSGS and HIVAN 
[Madhavan et al, 2011]. Based on these studies, we hypothesize that podocyte uptake of the 
exogenous APOL1 Vs could originate from smooth muscles of arteries and arterioles and 
contribute to accelerated podocyte injury. Thus, it is likely that smooth muscle cells may be 
serving either an endocrine or paracrine source of APOL1/APOL1Vs.
In the current study, we report the expression profile of APOL1 in arterial SMCs in an 
experimental HIV milieu, and have also examined the effects of smooth muscle cell 
APOL1Vs on human podocytes.
Materials and Methods
Cell Culture
Human podocytes were cultured as previously reported [Saleem et al, 2002; Hussain et al, 
2009]. Briefly, immortalized human podocytes proliferated in the growth medium 
containing RPMI 1640 supplemented with 10% fetal bovine serum, 1 X penicillin-
streptomycin, 1 mM L-glutamine, and 1 X insulin, transferrin, and selenium (ITS) 
(Invitrogen, Grand Island, NY) at permissive temperature (33°C). Podocytes at 80% 
confluence were transferred to 37°C for differentiation in a medium without ITS for 5–7 
days.
Human umbilical artery smooth muscle cells (HSMC) were purchased from ScienCell 
Research Laboratories (Carlsbad, CA), and were cultured with Smooth Muscle Cell Medium 
(SMC/CM, ScienCell) at 37°C.
Lentivirus preparation
APOL1 lentivirus was produced by transfection of 293T cells by using the Effectene 
Transfection Reagent (Qiagen), and the virus titer was determined by using QuickTiter 
Lentivirus Titer Kit (Cell Biolabs, San Diego, CA) as described [Lan et al, 2014].
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Preparation of Conditioned Media from APOL1 and APOL1Vs-transduced HSMCs and from 
HIV-infected immune cells
To collect conditioned media (CM) from smooth muscle cells, confluent HSMCs were 
transduced with lentivirus LG12-APOL1 (0.4 pg p24 protein/cell)[Lan et al, 2014 ]. To 
collect conditioned media (CM) from immune cells, PBMCs were isolated from blood as 
previously described [Mikulak et al, 2010], and infected with HIV strains NL4-3 (AIDS 
Reagent, NIH). After 3 h, the virus was removed, and the cells were rinsed with PBS, and 
were cultured in fresh RPMI medium with 10% FBS. Three days later, CM were harvested, 
cleared of free-floating cells by centrifugation for 5 min at 12000 rpm, and stored at −80ºC. 
Similarly, conditioned medium of HIV-infected U939 cells (U1 cells, monocytoid cell line, 
AIDS Reagent, NIH) was collected and stored until further use.
HIV infection of HSMCs
HSMCs at 80% confluence were infected with HIV-1 (NL4-3 strain, NIH AIDS Research 
and Reference Reagent Program, Germantown, MD) for 4 h, and then were cultured in 
RPMI medium containing 10% FBS at 37°C.
Doxycycline inducible APOL1-expressing HSMCs
A lentiviral expressing vector LW12-TetOn3G-Apol1 was constructed (Figure 1). Promoter 
PTRE3G was from plasmid pTRE3G (Clontech Laboratories, Mountain View, CA), and 
promoter PCMVIE and cDNA Tet-On 3G were from plasmid pCMV-Tet3G (Clontech 
Laboratories). Two primers APOL1-FW 
(GGAATTCATGGAGGGAGCTGCTTTGCTGAGAG, EcoRI cleavage site underlined) 
and APOL1-RV (GGGGTACCTCACAGTTCTTGGTCCGCCTGCAG, KpnI cleavage site 
underlined) were used to amplify the full length ORF of the APOL1 gene. Lentivirus was 
prepared following our previous protocol [Lan et al, 2014]. Human podocytes were 
transfected with these LW12-TetOn3G-APOL1/WT/Vs harboring virus for 5 days, and GFP 
positive cells were sorted by Fluorescence-Activated Cell Sorting (FACS). The resulting 
cells were cultured in SMC-CM for amplification and in RPMI medium containing 10% 
FBS for CM production.
Determination of APOL1 concentration
APOL1 concentrations in media were determined by ELISA with the Human APOL1 Kit 
(Proteintech Group Inc, Chicago, IL), according to the manufacturer’s instructions.
Trypan blue staining
Cells were rinsed with PBS (to remove the floating cells and cell debris), detached with 
Accutase (Innovative Cell Technologies, San Diego, CA), and then labeled with 0.2% 
Trypan blue and counted under a light microscope. The unstained cells (white cells) were 
counted as live cells, while the stained (blue) cells were counted as dead cells.
Propidium iodide (PI) and Hoechst staining
PI and Hoechst staining were performed as previously described [Lan et al, 2014]. Briefly, 
after each treatment condition of interest, the culture medium was removed from the cells 
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and fresh medium containing Hoechst 33342 (10 μg/ml) was added. Cells were subsequently 
incubated for 10 min at 37°C. Then, PI solution was added and culture dishes were kept on 
ice for 7 min. Cell images were recorded with a ZEISS microscope (Carl Zeiss Micro 
Imaging GmbH, Jena, Germany) equipped with a digital imaging system.
Assessment of lysosomal integrity
Control and experimental cells were stained with Lucifer Yellow (Invitrogen) and 
LysoTracker Red (Invitrogen) as described previously [Castro et al, 2004; Chandel et al, 
2013]. Briefly, cells were cultured overnight in medium containing 1 mg/ml Lucifer Yellow, 
and then 500 nM LysoTracker was added followed by another 30 min culture. Then the 
medium was removed, and the cells were rinsed 3 times with PBS. The cells were then fixed 
with 4% paraformaldehyde (PFA) for 10 min. Lysosomal imaging was carried under a 
fluorescence microscope (ZEISS)
Real time (RT) PCR
RT-PCR was performed as previously described [Lan et al, 2014], with addition of HIV-1 
Gag primers SK38/SK39: 5′-ATAATCCACCTATCCCAGTAGGAGA-3′ (Gag-FW), and 
5′-TTTGGTCCTTGTCTTATGTCCAGAATGC-3′ (Gag-RV).
Western blotting
Western blotting was performed as described previously [Lan et al, 2014]. Briefly, cells 
incubated under each treatment or corresponding control condition were washed with PBS 
and lysed in RIPA buffer (1 X PBS, pH7.4, 0.1% SDS, 1% NP-40, 0.5% sodium 
deoxycholate, 1.0 mM sodium orthovanadate, 10 μl of protease inhibitor cocktail (100 x, 
Calbiochem) per 1 ml of buffer, and 100 μg/ml PMSF). Proteins (20–30 μg) were separated 
by 12% SDS-polyacrylamide gel electrophoresis (PAGE) and then transferred on an 
Immuno-Blot polyvinylidene fluoride (PVDF) membrane (Bio-Rad, Hercules, CA). After 
blocking in PBS/Tween (0.1%) with 5% nonfat milk, the membrane was incubated with 
primary antibodies overnight at 4°C followed by horseradish peroxidase-conjugated 
secondary antibodies (1:3000, Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and then 
developed using Enhanced Chemiluminescent (ECL) solution (Pierce). Primary antibodies 
used were goat anti-APOL1 (1:1000, Acris Antibody, Inc., San Diego, CA, USA), and goat 
anti-actin (1:3000, Santa Cruz). For protein expression quantification, the films were 
scanned with a CanonScan 9950F scanner and the acquired images were then analyzed using 
the public domain NIH image program (http://rsb.info.nih.gov/nih-image/).
Depletion of APOL1 from conditioned media
Soluble APOL1 in CM was removed by using anti-APOL1 antibody. Briefly, 96-well 
microtiter plates (Costar) were coated overnight at 4°C with goat anti-APOL1 (0.5 μg/ml, 
Acris Antibody), in NaHCO3 solution (0.1 M, pH9.5). As a control, goat serum was used to 
coat the plates. Excess antibody was removed through washing with 0.1% Tween in PBS, 
three times and non-specific binding was blocked through exposure with 3% BSA in PBS 
for 6 hours. CM were incubated in these wells overnight at 4°C. Residual APOL1 in the CM 
was determined by ELISA. APOL1-free CM were used to treat human podocytes.
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Statistical analyses
Data are presented as means ± standard deviation (SD) unless otherwise noted. All 
experiments were conducted and repeated at least three times, either in duplicate or triplicate 
for each assay. All data were evaluated statistically by analysis of variance (ANOVA), 
followed by Newman-Keuls multiple comparison tests using Prism 4.0 GraphPad software. 
In the case of single mean comparison, data were analyzed by student t-test. P values < 0.05 
were regarded as statistically significant.
Results
APOL1 expression in HSMCs is increased in HIV milieu
Since arterial SMCs have been reported to be infected by HIV [Duchateau et al, 1997], we 
asked whether HIV infection of SMCs might increase their APOL1 expression. HSMCs 
were infected with HIV-1 strain NL4-3 for 1, 3, 6 and 9 days, and the expression of HIV 
Gag and APOL1 was quantified by RT-PCR. HIV Gag expression increased with the 
passage of time, consistent with HIV replication in HSMCs (Fig. 2A). HIV infection 
enhanced SMC expression of APOL1 up to five-fold at 72 hours, but the levels subsequently 
declined at later time points (Figure 2B). ELISA results also displayed a 2.5 fold increased 
secretory APOL1 in the medium at 72 hours but no further rise at the later time periods 
despite evidence of continued viral replication as indicated by continued rise of Gag 
expression (Figure 2C). Similar results were obtained by infecting SMCs with another 
primary HIV strain (92HT599) (data not shown). These results suggest that HIV infection 
enhances APOL1 expression, but does so only transiently and not in a manner which rises 
continuously in conjunction with the continued rise in HIV replication.
We then asked whether HIV-infected immune cells will affect APOL1 expression in 
vascular SMCs. Conditioned media (CM) of PBMC- infected with HIV NL4-3 or U939 
cells-infected with HIV (U1, monocytoid cell line) were collected after 3 days of infection. 
The CM were then used to treat HSMCs to examine the expression of APOL1. Western blot 
analysis revealed that both CM increased APOL1 expression in HSMCs (Figure 3A–B). 
PBMC/HIV-CM also significantly stimulated APOL1 secretion by HSMCs, and APOL1 
concentrations reached 1.0 ng/ml at 48 hours (Figure 3C).
To further confirm the induction of APOL1 expression in SMCs by exogenous factors, we 
treated HSMCs with IFN-γ. Western blot analysis showed that IFN-γ stimulated APOL1 
expression in both a dose- and time-dependent manner (Figure 4A–D). IFN-γ also increased 
APOL1 secretion by HSMCs in a time dependent manner (Figure 4E). At the end of 72 
hours, the concentration of APOL1 in media reached up to 5 ng/ml. Taken together, the 
foregoing results suggest that HSMCs in the inflammatory milieu (interaction with PBMC/
HIV-CM) could potentially have a role in vascular and glomerular injury.
HSMC/APOL1Vs induce human podocyte injury
First, we assessed baseline APOL1 expression in HSMCs. After culturing HSMCs for 24, 
48, and 72 h, we collected both cell lysates and medium for Western blot and for ELISA, 
respectively. We found that in the cell lysates, APOL1 expression did not increase with the 
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passage of time (Figure 5A–B). APOL1 in the medium accumulated slowly, but only 
reached concentrations approaching 0.01 ng/ml at 72 h (Figure 5C), indicating that the 
baseline APOL1 expression in HSMCs was very low when compared to the concentrations 
in the inflammatory milieu.
We then overexpressed APOL1Vs (G1 and G2) as well as APOL1WT (G0) in HSMCs 
employing a lentivirus expression system, as previously reported [Lan et al, 2014]. HSMCs 
were transduced with equal quantities of APOL1WT or APOL1Vs lentivirus (titrated as 0.4 
pg p24 protein/cell). After 48 h, only very few cells (less than 0.1%) showed swelling or 
necrosis in APOL1G1/G2, and no cell swelled in APOL1WT or vector control. Cells were 
harvested for protein blots and media were collected for determination of APOL1 
concentrations by ELISA. HSMCs displayed overexpression of APOL1WT and APOL1Vs 
(Figures 5D–E). ELISA concentrations of APOL1 secreted into the medium by SMCS/Vec 
were minimal (< 0.01 ng/ml at 48 hpi), whereas HSMC/APOL1WT and HSMC/
APOL1G1/G2 displayed increased APOL1 secretion (3–5 ng/ml) (Fig. 5F), representing 
more than 300-fold elevated APOL1 secretion.
To test the hypothesis whether APOL1 secreted by HSMCs exerts an endocrine/paracrine 
effect on podocyte phenotypes, we co-cultured HSMCs and human podocytes in a double 
chamber (Figure 6A). HSMCs were cultured in the bottom chamber and then transduced 
with lentivirus LG12-APOL1. After 48 h, differentiated human podocytes were cultured in 
the upper chamber. In this experimental system, HSMC- secreted proteins have access to the 
co-cultured podocytes through the filter. After 3 days of co-culture, podocytes were assessed 
for their viability by Trypan Blue staining. Podocyte co-cultured with HSMC/APOL1 WT 
displayed augmented cell death and this effect was markedly more prominent in podocytes 
co-cultured with either HSMC/APOL1G1 or HSMC/APOLG2 (Figure 6B).
In order to account for possible concentration differences and disentangle this from to the 
effect of the different molecular structures of the WT vs. Vs moieties of APOL1, we 
conducted dose dependency studies. HSMCs were transduced with half the dose of 
lentivirus (titrated as 0.2 pg p24 protein/cell) for 3 hours and then incubated in fresh media 
for 48 hours. Co-culture with human podocytes was performed, and living cells were 
counted. As shown in Figure 6C, at these reduced transfection doses, APOL1WT-expressing 
HSMCs did not display overt podocyte injury; on the other hand, HSMCs-expressing 
APOLG1 or G2 displayed a decreased percentage of viable cells even at this reduced 
dosage. These findings indicate that APOL1-induced podocyte injury was dependent on 
concentration as well as conformation of APOL1, such that the risk variants have a lower 
dose threshold for inducing injury.
To confirm the role of HSMC-CM in podocyte injury, we collected the conditioned media 
from over expressing APOL1WT and APOL1Vs HSMCs and evaluated the effect of these 
CM on podocytes. CM-G1 and CM-G2, but not CM-WT, induced podocyte swelling and 
death (Figure 7A–C). G1-CM and G2-CM induced apoptosis, necrosis, and secondary 
necrosis in a significantly greater percentage of podocytes when compared to podocytes 
treated with WT-CM. (Figure 7D–E).
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To determine the effects of CM on lysosomal integrity, Lucifer Yellow and LysoTracker 
Red staining was performed. APOL1Vs enhanced lysosomal leakage and decreased the 
LysoTracker Red staining, indicating that CM-G1 and CM-G2 increased lysosomal 
membrane permeability (LMP) (Figure 7F–H). On the other hand, a chloride channel 
blocker significantly decreased CM-Vs-induced podocyte injuries (Figure 7I); while HIV 
transduction significantly increased CM-Vs-mediated podocyte death (Figure 7J).
To validate the role of APOL1 Vs in the CM-induced podocyte injuries, we used microtiter 
plates to remove the APOL1 proteins from SMC-CMs. ELISA assay results showed that the 
anti-APOL1 antibody could successfully remove almost all the APOL1 protein from the 
CM, while the goat serum control did not (data not shown). Human podocytes were treated 
with CM and cell injury was determined by counting live cell ratios. APOL1 depletion from 
the CM, significantly decreased podocyte injury (Figure 8). These findings indicate that 
podocyte injury was partially mediated through the cytotoxicity of APOL1Vs secreted into 
the media.
To further validate these results, we established stabile cell lines over-expressing APOL1 
under the control of Tet-on system (Fig. 1). After sorting, more than 95% of the cells were 
GFP positive even after 3 passages, indicating that the ectopic inducible transgenes could be 
stably expressed in these cells. Doxycycline (100 ng/ml) was added to the medium, and the 
cells were cultured at 37°C for 4 days. ELISA results showed that doxycycline successfully 
induced APOL1 production and secretion (Figure 9A). The medium was collected as CM 
and was used to treat human podocytes. After another 48 h, cell injury was measured by 
counting alive cell ratio. CM-Vs (Doxy) also showed podocyte cytotoxicity, while CM-WT 
(Doxy) didn’t induce podocyte cytotoxicity (Figure 9B). These results confirmed the 
podocyte cytotoxicity of APOL1Vs derived from HSMCs.
Discussion
Vascular smooth muscle cells are important constituents of arterial walls and among other 
functions regulate the caliber of the blood vessels. Contractility of these cells serves to 
regulate perfusion to body organs. Additionally, vascular SMCs are an important source of 
interleukins, chemokines and growth factors in several organ systems [Gerthoffer and 
Singer, 2002]. Since vascular SMCs were shown to express of APOL1 in renal biopsy 
specimens of patients with HIVAN and FSGS [Madhavan et al, 2011], and the APOL1 gene 
product is a secreted protein, it is likely that arterial smooth muscle cells may be 
contributing to the APOL1 content of blood perfusing glomerular capillaries. In the present 
study, we demonstrated that both HIV-CM and IFN-γ enhanced APOL1 production by 
vascular SMCs. APOL1Vs displayed an overt toxicity in response to podocytes, whereas, 
APOL1WT was toxic to podocytes only at higher concentration. Depletion of APOL1 from 
the CM mitigated podocyte toxicity, confirming that it is APOL1 in the CM which is 
directly responsible for the induction of podocyte injury under these experimental 
conditions. These results indicate that vascular SMCs carry the potential to contribute to 
podocyte injury through generation of APOL1/APOL1Vs and that there is a disparity in the 
toxicity of the WT compared to the risk APOL1Vs. This is the first report to validate a 
causal relationship between the upregulation of HSMC/APOL1 and podocyte injury.
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Although HIV infection displayed the potential to enhance smooth muscle cell expression of 
APOL1 during the time course examined, this response was not sustained over time, nor did 
it correlate with the continuous increase in viral replication. Moreover, data on HIV 
infection of smooth muscle cells are limited (Eugenin et al, 2008). Therefore, more studies 
are needed to confirm productive HIV infection of smooth muscle cells. Furthermore, 
secretion of APOL1 by HIV/HSMCs was relatively low (only 5%) when compared to the 
secretory potential of conditioned media of HIV-infected PBMCs and U939 cells. Thus, it 
appears that APOL1 expression maybe more likely attributed to the HIV milieu (secretory 
products of HIV-infected immune cells) rather than direct HIV infection. The HIV milieu 
contains interferons and other antiviral innate immune molecules [Benlahrech and Patterson, 
2011; Segal et al, 2012]. It has been reported that IFN-γ can dramatically increase APOL1 
expression in podocytes, renal endothelial cells, and other cells [Nichols et al, 2014; 
Zhaorigetu et al, 2008]. Consistent with these reports, we also found that both PBMC/HIV-
CM and recombinant IFN-γ could enhance APOL1 expression in HSMCs. These findings 
provide a mechanistic insight into enhanced occurrence of FSGS in patients with HIV 
infection.
Notably, in the present study, APOL1 depletion from the CM provided only partial 
protection against podocyte injury. Therefore, it is likely that under these phlogogenic 
conditions, SMCs may also be secreting other inflammatory mediators which are also 
injurious to podocytes. Since SMCs are known to secrete interleukins [Gerthoffer and 
Singer, 2002], it will be interesting to investigate the effect of APOL1Vs on the production 
of inflammatory cytokines such as IL-1β and IL6 in future studies.
Although we have confirmed that HIV-CMs and IFN-γ have the potential to enhance the 
production of APOL1 by SMCs, the detailed mechanism is far from clear. P53 has been 
reported to regulate APOL1 expression in endometrial cancer cell [Wan et al, 2008]. It will 
be interesting to investigate whether P53 also plays a role in the regulation of HIV-induced 
APOL1 expression in SMCs in future studies. APOL1 has also been shown to be involved in 
autophagy, and podocytes are critically dependent on a careful balance of autophagic flux 
pathways, and also on intact endososomal trafficking, so that disruption of one or more key 
molecules in these pathways may also have a cardinal role [Wan et al, 2008; Weide and 
Huber, 2011; Bechtel et al, 2013].
In a recent report, no correlation was observed between circulating APOL1 levels with HIV 
infection status or inflammatory mediators in an HIV positive cohort with kidney disease 
(Bruggeman et al, 2014). This makes it all the more relevant to consider local effects, 
whether they be APOL1 that is produced and acting by an endogenous intracellular 
mechanism, or via paracrine exposure from adjacent cell. In the present study, HIV 
transiently increased APOL1 production by vascular smooth muscle cells and direct HIV 
infection did not enhance smooth muscle cell APOL1 expression significantly. Since there 
was no relationship between severity of HIV infection and development of kidney disease, 
we speculate that APOL1- induced vulnerability to HIV effects are more critical for the 
development of HIVAN rather than the level of viral load; on that account, it seems of 
paramount importance to delineate the mechanism for APOL1-induced podocyte injury in 
an HIV milieu. Another example of a sharp disparity between circulating levels and local 
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intra-renal mechanisms has been well studied, and that is the renin angiotensin system 
(RAS), wherein local activation may predominate in physiologic, pathophysiologic and 
pharmacologic responses [Gonzalez-Villalobos et al, 2013]. By analogy, it is important to 
consider and examine the effects of local production of APOL1 by either smooth muscle 
cells or kidney cells to the manifestation of kidney disease. Therefore, the theme of the 
present study was to test whether smooth cells have the potential to serve as a source of 
secretory APOL1 in the presence or absence of HIV infection. Interestingly, levels of viral 
load in HIV patients correlate better with low CD4 T cell count (Segal et al., 2012). On that 
account, a higher level of viral load would be associated with a decreased pool of T cells. 
Since local generation of T cell cytokines may be modulating smooth muscle cell APOL1 
expression, this may not necessarily correlate with viral load. However, the present study 
clearly demonstrates that it is not the HIV-infected smooth muscle cells but rather 
interaction between HIV infected T cells with smooth muscle cells which serve as a 
potentially relevant source of APOL1 production for kidney injury. Interestingly, this may 
also provide an explanation for the lack of correlation between the circulating viral load/ 
cytokine mediators and APOL1 levels in HIVAN patients (Bruggeman et al, 2014). 
Additionally, human biopsy data support our notion that smooth muscle cells express 
APOL1 and that its expression is increased in patients with HIVAN (Madhavan et al, 2011). 
Whether, this increase in APOL1 expression in HIVAN patients can be attributed to smooth 
muscle cell HIV infection is a conjecture. While the results of the study are consistent, they 
do not definitively refute nor confirm this conjuncture, but provide the lead needed to 
rationalize in vivo or clinical investigation.
APOL1-associated kidney disease may lead to secondary hypertension and this phenomenon 
is often mistaken for essential hypertension as the initiator of chronic kidney disease [Kopp, 
2013; Skorecki and Wasser, 2013; Ito et al, 2014]. We previously suggested that prognosis 
of hypertension-attributed kidney disease between AAs and EAs is not dependent on their 
blood pressure control but a reflection of differences in their genetic vulnerability of kidney 
cell injury [Skorecki and Wasser, 2013]. We further speculate that smooth muscle cells in 
AAs may be acting as a source of circulating APOL1Vs. In such a scenario, uptake of 
circulating APOL1Vs by podocytes may be contributing to the initiation and progression of 
FSGS in this population. In this regard, it is important to note that APOL1 has a signal 
peptide [SP] and moreover that multiple splice variants some of which may not bear the SP 
have been described, and moreover it is known that splicing variation can be influenced by 
viral, inflammatory and oncogenic signals [Tzur et al, 2010; Skorecki and wasser, 2013]. 
Therefore, depletion or inhibition of APOL1Vs may be a logical approach, in addition to 
meticulous blood pressure control to prevent or slow the progression of chronic kidney 
disease.
Patients with HIV infection have been reported to have greater incidence of coronary artery 
disease and atherosclerosis [Falusi and Aberg, 2001]. Partly, this may be related to 
dysplipidemia associated with anti-retroviral therapy [Duro et al, 2013]. It has also been 
suggested that HIV-Nef protein has a potential to block the efflux of cholesterol from their 
intracellular stores and therefore cells such as macrophages may convert into foam cells 
[Mujawar et al, 2010]. Moreover, ongoing lipid peroxidation may also contribute to 
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enhanced atherosclerosis in patients with HIV infection [Cui et al, 2014]. Diamond and 
Karnovsky proposed that both atherosclerosis and focal segmental glomerulosclerosis have 
similar mechanisms involved for their development and progression [Diamond and 
Karnovsky, 1988]. In both cases, there is influx of macrophages, subintimal space in case of 
atherosclerosis and mesangial region in case of FSGS, contribute to the respective 
phenotype. In both instances, HIV milieu may be serving as a source of interferon-gamma 
and may thus enhance APOL1 expression by SMCs. Whether modulation of APOL1Vs 
expression in the altered cytokine milieu also contributes to deleterious or beneficial effects 
in the development of cardiovascular events remains a controversial issue at present [Ito et 
al, 2014; Freedman et al, 2015; Langefeld et al, 2015].
In summary, APOL1 expression in vascular SMCs can be dramatically increased in HIV 
milieu, and has the potential to serve as an endocrine/paracrine source. Extracellualr APOL1 
can be taken up by podocytes, leading to cytotoxicity. In case of podocyte uptake of 
APOL1Vs, the magnitude and or rate of podocyte loss may be several folds higher, which 
may overwhelm the repair capability of the vulnerable population [Wiggins et al, 2014]. The 
present study provides additional mechanistic insight into occurrence of accelerated loss of 
podocytes and possibly vascular involvement in HIV milieu in patients carrying the kidney 
disease risk variants of APOL1.
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Highlights
• Human artery smooth muscle cells (HSMC) displayed enhanced expression of 
APOL1 in HIV milieu
• Podocytes co-cultured with HSMC-expressing APOL1G1 or APOL1G2 showed 
several fold greater injury
• Conditioned media collected from HSMC-expressing APOL1G1/APOL1G2 
also inflicted injury in higher percentages of podocytes.
• HSMCs could serve as an endocrine/paracrine source of APOL1Vs, which 
mediate accelerated podocyte injury in HIV milieu.
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Figure 1. 
Schematic diagram of lentiviral expressing vector LW12-TetOn3G-apol1
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Figure 2. Effects of HIV infection on APOL1 expression in SMCs
SMCs were transduced with HIV NL4-3 for 3 h, washed and re-incubated in fresh medium.
Cells and media were harvested at days 1, 3, 6 and 9.
A–B. RNA was extracted and the expression of HIV Gag and APOL1 was detected by RT-
PCR.
C. APOL1 concentrations in incubation media were determined with ELISA kit.
The results (mean ± SD) are from three independent sets of experiments carried out in 
triplicate.
* p < 0.05 vs. control.
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Figure 3. Effects of immune cell/HIV-conditioned media on APOL1 expression in SMCs
SMCs were treated with conditioned medium collected from HIV (NL4-3 or U1)-infected 
PBMCs (n=3). After 48 h, cells and incubation media were harvested for Western blot assay 
and ELISA respectively.
A. Protein blots were probed for APOL1, stripped and re-probed for actin.
B. Cumulative densitometric data from of three independent experiments shown as bar 
graphs.
* p < 0.05 compared to control
C. APOL1 concentrations in incubation media were determined with an ELISA kit. The 
results (mean ± SD) represent three sets of experiments carried out in triplicate.
* p < 0.05 compared with control.
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Figure 4. Effects of IFN-γ on APOL1 expression in HSMCs
A. SMCs were treated with recombinant human IFN-γ for 36 hours at the concentrations 
indicated (n=3). Protein blots were probed for APOL1 and the same blots were stripped and 
reprobed for actin.
B. Cumulative densitometric data shown in bar graphs. * p < 0.05 compared with control.
SMCs were treated with 10 ng/ml of recombinant human IFN-γ for the indicated time 
periods (n=3). Subsequently, cells and incubation media were harvested.
C. Protein blots were probed for APOL1, stripped and reprobed for actin.
D. Cumulative densitometric analysis shown in a bar diagram. * p < 0.05 compared with 0, 
12, 48, and 72 h.
E. APOL1 concentrations in incubation media were determined by ELISA. * p < 0.05 
compared with control.
Lan et al. Page 19
Exp Mol Pathol. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 5. Overexpression of APOL1 in human vascular smooth muscle cells
A–C: HSMCs were cultured in SMCM until reaching 80–90% confluence, and were 
transferred to RPMI medium. After another 24, 48, and 72 h, cell lysates and medium were 
collected for detection of APOL1 with Western blots (A-B) and ELISA (C), respectively.
D–F: HSMCs were infected with lentivirus (titrated as 0.4 pg HIV p24 protein per cell) for 3 
h, and then re-incubated in fresh medium for 48 h (n=3). Cells and media were collected.
D. Protein blots were probed for APOL1, stripped and re-probed for actin.
E. Densitometric analysis shown as bar graphs. * p < 0.05 compared with control (vector).
F. APOL1 concentrations were determined in media with an ELISA kit.
Results (mean ± SD) are from three sets of experiments carried out in triplicate. * p < 0.05 
compared with control (vector). Vec, vector alone; WT, APOL1 wild type; G1, APOL1 G1 
variant; G2, APOL1 G2 variant.
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Figure 6. Co-culture of podocytes with APOL1 risk variants-producing vascular smooth muscle 
cells
A. Schematic diagram of co-culture of podocytes and HSMCs.
B. HSMCs at the bottom of 6-well plates were transduced with lentivirus (titrated as 0.4 pg 
HIV p24 protein per cell). After for 3 h, the cells were washed with PBS, and reincubated in 
fresh medium. At 24 hpi, inserts containing human podocytes on the filter were inserted. 72 
hours later, the inserts were taken out, and the cells were subjected to Trypan Blue staining 
to count the alive cells. * p < 0.05 compared with vector, while # p < 0.05 compared to 
APOL1WT.
C. SMCs were transduced with half the dose of APOL1-gene harboring virus (0.2- 0.4 pg 
HIV p24 protein per cell), and alive podocytes were counted after co-cultured as mentioned 
above. * p < 0.05 compared with vector, while # p < 0.05 compared to APOL1WT.
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Figure 7. Conditioned medium of SMCs promote podocyte injuries
HSMCs were transduced with lentivirus (titrated as 0.4 pg HIV p24 protein per cell) for 3 h, 
and reincubated in fresh medium (n=3). At 72 hpi, the media were collected. After 
centrifugation, supernatants were collected (conditioned media, CM), and added to human 
podocytes in 6-well plates.
A. Podocytes were treated with either HSMC/Vector-CM, HSMC/APOLWT-CM, HSMC/
APOL1G1-CM, or HSMC/APOL1G2-CM for 48 hours (n=3). Cells were stained with 
Trypan blue and dead cells were counted by two investigators, unaware of the experimental 
conditions. * p < 0.05 compared to HSMC/Vector-CM, while # p< 0.05 compared to 
HSMC/-APOL1WT-CM.
B. Podocytes were treated with either HSMC/Vector-CM, HSMC/APOLWT-CM, HSMC/
APOL1G1-CM, or HSMC/APOL1G2-CM for 48 hours (n=3). Subsequently, cells were 
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examined under a phase microscope. Representative microphotographs of swollen cells are 
shown. Scale bar: 100 μm.
C. Cumulative data on percentage of swollen cells in each subgroup. Results (mean ± SD) 
are from three sets of experiments. * p < 0.05 compared to HSMC/Vector-CM, while # p< 
0.05 compared to HSMC/APOL1WT-CM.
D. Podocytes were treated with either HSMC/Vector-CM, HSMC/APOLWT-CM, HSMC/
APOL1G1-CM, or HSMC/APOL1G2-CM for 48 hours (n=3). Subsequently, cells were 
subjected to PI/Hoechst staining and then examined under an immunofluorescence 
microscope. Representative microphotographs are displayed showing apoptotic (green 
arrow), necrotic (white arrow), and secondary necrotic (yellow arrow) cells. Scale bar: 50 
μm.
E. Cumulative data on percentage of apoptotic and necrotic cells in each subgroup are 
shown. Results (mean ± SD) are from three sets of experiments. * p < 0.05 compared with 
HSMC/Vector-CM, # p < 0.05 compared to HSMC/APOL1WT-CM
F. Podocytes were treated with either HSMC/Vector-CM, HSMC/APOLWT-CM, HSMC/
APOL1G1-CM, or HSMC/APOL1G2-CM for 48 hours (n=3). Podocytes were subjected to 
LysoTracker Red and Lucifer Yellow and examined under an immunofluorescence 
microscope. Representative microphotographs are displayed. Scale bar: 10 μm.
G. Cumulative data for each variable of the protocol F (Lyso Tracker Red labeling) are 
displayed in bar graphs. Results (mean ± SD) are from three sets of experiments. * p < 0.05 
compared to HSMC/Vector-CM, # p < 0.05 compared to HSMC/APOL1WT-CM
H. Cumulative data for each variable of the protocol F (Lucifer Yellow labeling) are 
displayed as bar graphs. Results (mean ± SD) are from three sets of experiments. * p < 0.05 
compared to HSMC/Vector-CM, # p < 0.05 compared to HSMC/APOL1WT-CM
I. Podocytes were treated with either HSMC/Vector-CM, HSMC/APOLWT-CM, HSMC/
APOL1G1-CM, or HSMC/APOL1G2-CM in the presence or absence of DIDS (100 μM, a 
chloride channel blocker) for 48 hours (n=3). Subsequently, cells were stained with Trypan 
blue and dead cells were counted. * p < 0.05 compared to respective variables.
J. Empty vector or NL4-3(HIV)-transduced podocytes were incubated in media containing 
either HSMC/Vector-CM, HSMC/APOLWT-CM, HSMC/APOL1G1-CM, or HSMC/
APOL1G2-CM for 48 hours (n=3). Subsequently, cells were stained with Trypan blue and 
dead cells were counted. * p < 0.05 compared to respective variables.
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Figure 8. APOL1 depletion attenuates CM-induced podocyte injury
HSMC-CM were incubated in micro titer plates coated with anti-APOL1 antibody (+) or 
goat serum control (-). After overnight, media were collected. Podocytes were treated with 
these media for 48 hours (n=3). Subsequently, podocytes were assayed for viability. * p < 
0.05 compared with respective variables.
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Figure 9. Doxycycline induced APOL1Vs from HSMCC cause podocyte injury
After FACS sorting, LW12-TetOn3G-APOL1/WT/Vs harboring HMSCs were cultured in 
SMCM to around 80–90% confluence, and then were changed to RPMI medium containing 
10% FBS and 100 ng/ml doxycycline. After another 4 days, the medium was collected, and 
free-floating cells were cleared by centrifugation. APOL1 concentrations in the collected 
CMs were determined by ELISA (A). The CMs were used to treat differentiated human 
podocytes in cell culture dishes, and the cells were subjected to Trypan Blue staining to 
count the alive cells (B). * p < 0.05 compared with vector, while # p < 0.05 compared to 
APOL1WT.
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Figure 10. 
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